A new cure for sickle cell disease may be coming. FDA advisers will review it next week.
The only cure for painful sickle cell disease today is a bone marrow transplant. But soon there may be a new cure that attacks the disorder at its genetic source. On Tuesday, advisers to the Food and Drug Administration will review a gene therapy for the inherited blood disorder, which in the U.S. mostly affects Black people. Issues they will consider include whether more research is needed into possible unintended consequences of the treatment. If approved by the FDA, it would be the first gene therapy on the U.S. market based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. The The post A new cure for sickle cell disease may be coming. FDA advisers will review it next week. appeared first on HBCU News.
The only cure for painful sickle cell disease today is a bone marrow transplant. But soon there may be a new cure that attacks the disorder at its genetic source. On Tuesday, advisers to the Food and Drug Administration will review a gene therapy for the inherited blood disorder, which in the U.S. mostly affects Black people. Issues they will consider include whether more research is needed into possible unintended consequences of the treatment. If approved by the FDA, it would be the first gene therapy on the U.S. market based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. The
The post A new cure for sickle cell disease may be coming. FDA advisers will review it next week. appeared first on HBCU News.
/cloudfront-us-east-1.images.arcpublishing.com/gray/BFMUKWSWURCKTM4CQOY4DVUYOA.jpg)
